Advertisement
UK markets open in 2 hours 12 minutes
  • NIKKEI 225

    37,693.92
    -766.16 (-1.99%)
     
  • HANG SENG

    17,295.93
    +94.66 (+0.55%)
     
  • CRUDE OIL

    82.93
    +0.12 (+0.14%)
     
  • GOLD FUTURES

    2,325.20
    -13.20 (-0.56%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • Bitcoin GBP

    51,566.21
    -2,000.02 (-3.73%)
     
  • CMC Crypto 200

    1,387.47
    -36.63 (-2.57%)
     
  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     
  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     

Are You Looking for a Top Momentum Pick? Why Syros Pharmaceuticals, Inc. (SYRS) is a Great Choice

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

Below, we take a look at Syros Pharmaceuticals, Inc. (SYRS), which currently has a Momentum Style Score of B. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Syros Pharmaceuticals, Inc. Currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.

ADVERTISEMENT

You can see the current list of Zacks #1 Rank Stocks here >>>

Set to Beat the Market?

Let's discuss some of the components of the Momentum Style Score for SYRS that show why this company shows promise as a solid momentum pick.

Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.

For SYRS, shares are up 5.54% over the past week while the Zacks Medical - Biomedical and Genetics industry is flat over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 29.54% compares favorably with the industry's 1.64% performance as well.

While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Shares of Syros Pharmaceuticals, Inc. Have increased 201.71% over the past quarter, and have gained 61.93% in the last year. In comparison, the S&P 500 has only moved 8.79% and 20.49%, respectively.

Investors should also pay attention to SYRS's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. SYRS is currently averaging 234,800 shares for the last 20 days.

Earnings Outlook

The Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with SYRS.

Over the past two months, 2 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost SYRS's consensus estimate, increasing from -$4.86 to -$4.82 in the past 60 days. Looking at the next fiscal year, 2 estimates have moved upwards while there have been no downward revisions in the same time period.

Bottom Line

Taking into account all of these elements, it should come as no surprise that SYRS is a #2 (Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Syros Pharmaceuticals, Inc. On your short list.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Syros Pharmaceuticals, Inc. (SYRS) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research